Boltz raises $110M Series A led by Bessemer Venture Partners
On November 18, 2026, Boltz, a public benefit company that builds AI models for drug molecules, announced a $110 million Series A led by Bessemer Venture Partners, according to Bessemer's announcement and Endpoints News. Other named backers include a16z, Amplify Partners, Obvious Ventures, F-Prime Capital and Greycroft. No valuation was disclosed. The round is about 3.9 times the $28 million seed the company announced in January.
Boltz sells access through molecular tokens, which measure the molecular information processed per task, so a quick prediction costs little while a full design campaign costs much more. The company says token usage from its users rose 50-fold since June, while a16z investors describe roughly 50-fold growth over four months. Six of the 20 largest drugmakers are partners. Under a January Pfizer collaboration, Boltz tunes its models on Pfizer's historical data to build exclusive versions, and Pfizer keeps ownership of compounds it develops. The earlier open models are free to download, while the newer models and Boltz Lab are paid.
CEO Gabriele Corso is steering the company toward a paid biopharma software product called Boltz Labs, according to Endpoints News. Boltz Lab, the hosted platform, began commercial use in January. Bessemer's Andrew Hedin and Byron Deeter are joining the company, according to WOWTALE.
Why it matters
For founders building scientific AI, the round suggests open models can build a user base that converts into paid usage once teams run them in production. Metering by tokens mirrors how labs already budget for sequencing reads and assay reagents, which may make the spend easier to justify. The open core also means rivals can download the same base models, so differentiation has to come from the paid layer.
For operators and investors, the usage figures come from the company and a16z rather than audited data. Buyers and investors should check them against pilot-to-contract conversion, renewal rates and how many customers pay each month. With no valuation disclosed, return math cannot be tested yet. Exclusive deals like Pfizer's may matter more for revenue than download counts.
Key points
- 1Bessemer Venture Partners led Boltz's $110 million Series A, and no valuation was disclosed.
- 2Boltz launched in January with a $28 million seed led by Amplify, a16z and Zetta Venture Partners.
- 3The company says molecular token usage from its users rose 50-fold since June.
- 4Six of the world's 20 largest pharma companies are partners, according to the company.
- 5Bessemer's announcement says Boltz's open-source models have been downloaded over 5 million times.